ARNA : Analysis & Opinions

  1. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  2. Vivus Unveils Qsymia Study Results - Analyst Blog

    February 7, 2013
    Vivus Inc. (VVUS) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. Results ...
  3. Update on Orexigen's Contrave - Analyst Blog

    January 10, 2013
    Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, which had ...
  4. Takeda Terminates Amylin Agreement - Analyst Blog

    December 31, 2012
    Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement ...
  5. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  6. Arena Cuts Loss, Affirms Sales View - Analyst Blog

    November 9, 2012
    Arena Pharmaceuticals Inc.'s (ARNA) loss (excluding special items) of 7 cents per share in the third quarter of 2012 was ...
  7. Vivus Misses 3Q Estimates - Analyst Blog

    November 8, 2012
    Vivus Inc. (VVUS) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus Estimate ...
  8. Weight Watchers May Be The Best House On An Awful Street

    November 6, 2012
    Weight Watchers continues to struggle to exploit its huge market opportunity.
  9. CHMP Negative on Vivus' Qsiva - Analyst Blog

    October 22, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  10. Vivus Expects European Setback - Analyst Blog

    September 25, 2012
    Vivus Inc. (VVUS) recently announced that it expects the European Medicines Agency's (EMA) Committee for Medicinal Products ...
  11. Vivus Launches Obesity Drug Qsymia - Analyst Blog

    September 20, 2012
    Vivus Inc. (VVUS) recently announced the launch of its obesity drug, Qsymia, in the US following the US Food and Drug Administration's ...
  12. Biogen Idec and Other Big Movers In Healthcare on September 6, ...

    September 6, 2012
    The morning has been good for the market. The Nasdaq has risen 1.9%; the S&P 500 is up 1.8%; and the Dow has moved up 1.7%. ...
  13. Buy or Sell? Wednesday's Winners: GWRE, OREX

    September 5, 2012
    Among the biggest winners in Wednesday's early trading are Guidewire Software (Nasdaq: GWRE) and Orexigen Therapeutics (Nasdaq: ...
  14. Nasdaq's Biggest Movers, Including PEET, for July 23, 2012

    July 23, 2012
    After a bad morning, the Nasdaq has decreased 1.9%, the S&P 500 has slipped 1.3% and the Dow is down 1.1%. The Nasdaq ...
  15. Healthcare Stocks Making Big Moves on July 18, 2012

    July 18, 2012
    The morning has been good for the market. The Nasdaq has risen 1.2%; the S&P 500 is up 0.6%; and the Dow has moved up 0.7%. ...
  16. Healthcare Sector's Biggest Movers for July 5, 2012

    July 5, 2012
    So far today, the Nasdaq has moved up 0.3%, the S&P 500 is trading down 0.2% and the Dow has declined 0.1%. The healthcare ...
  17. Biggest Healthcare Sector Movers for July 2, 2012

    July 2, 2012
    The market is currently down, with the Nasdaq falling 0.2%, the S&P 500 down 0.2% and the Dow decreasing 0.5%. The healthcare ...
  18. Control May Be Herbalife's Real Long-Term Problem

    June 4, 2012
    Herbalife's model may not be as precarious as feared, but there are some weaknesses and the stock may only see 10% compound ...
  19. Countdown Has Begun for 7 Rising Biotechs

    March 13, 2012
    If you're looking for cutting-edge companies that have a chance to triple or quadruple in the coming months and years, don't ...
  20. Nutrisystem Still Searching For Sustainability

    March 12, 2012
    Nutrisystem's membership weakness is a worrisome sign.
  21. Wall Street Isn't Buying The Medifast Story

    March 5, 2012
    Medifast gets a lot of doubt on the Street.
  22. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  23. Vivus Tries A New Path

    September 21, 2011
    Vivus takes a more pragmatic approach to getting Qnexa to market.
  24. Transcept Pharmaceuticals Bulls Get Rude Awakening

    July 15, 2011
    Transcept gets a major setback, but it may not be doomed.
  25. Fattening Up A Portfolio While Slimming Down

    June 1, 2011
    With the numbers of overweight and obese people growing globally, investors may want to consider stocks on the front lines ...
  26. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  27. FDA Locked And Loaded For MELA Sciences

    November 16, 2010
    A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
  28. Vivus Gets An Encouraging “No”

    October 29, 2010
    Vivus gets a big boost of encouragement from a benign FDA rejection.
  29. Orexigen Finds A Cautious Partner

    September 3, 2010
    Orexigen gets the going rate for an obesity drug with low expectations.
  30. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center